ライフサイエンスコーパス: biodefense

1 es pose serious threats to public health and biodefense.

2 is, and EEEV is a select agent of concern in biodefense.

3 ose significant threats to public health and biodefense.

4 life sciences research for public health and biodefense.

5 ose significant threats to public health and biodefense.

6 molecular biology, clinical diagnostics and biodefense.

7 diagnostics, blood screening, forensics and biodefense.

8 larensis is a category A agent of biowarfare/biodefense.

9 onotic disease tularemia and is important to biodefense.

10 tbreaks, development of antiviral drugs, and biodefense.

11 ns, including emerging viruses and agents of biodefense.

12 nd provides additional tools in medicine and biodefense.

13 ose significant threats to public health and biodefense.

14 ose significant threats to public health and biodefense.

15 To address critical unmet needs in biodefense against anthrax, we have designed a novel vac

16 erapeutics to treat infections caused by the biodefense agent Bacillus anthracis.

17 tularemia and is classified as a category A biodefense agent by the Centers for Disease Control and

18 ing febrile illness caused by the category A biodefense agent Francisella tularensis.

19 Tularemia is caused by the category A biodefense agent Francisella tularensis.

20 perfringens type D isolates are important in biodefense and also cause natural enterotoxemias in shee

21 ng pathogens that are currently an important biodefense and antibiotic resistance concern.

22 Decreasing this interval could be crucial in biodefense and cancer immunotherapy, in which rapid prot

23 ny fields including bioaerosol detection for biodefense and cellular diagnostics for clinical medicin

24 tained through National Institutes of Health Biodefense and Emerging Infections (BEI) resources devia

25 ry for the Regional Centers of Excellence in Biodefense and Emerging Infectious Diseases (NSRB) again

26 seases' 'Bioinformatics Resource Centers for Biodefense and Emerging or Re-Emerging Infectious Diseas

27 t of safe and effective therapeutics against biodefense and high-priority pathogens, including filovi

28 or ionizing radiation could be important for biodefense and in the treatment of acute injuries.

29 he detection of biological threat agents for biodefense and pathogens for the prevention of sepsis an

30 d the advancement of quantitative assays for biodefense and pharmaceutical applications.

31 ssay platform (SpinDx) to address the urgent biodefense and public health need for ultrasensitive poi

32 analysis resource for the study of specific biodefense and public health pathogens-Influenza virus,

33 A new methodology toward biodefense and threat surveillance by water-dispersible,

34 f fields from catalysis, molecular analysis, biodefense, and molecular biology.

35 early diagnosis of gene-related disease and biodefense application.

36 ensity resequencing GeneChips have potential biodefense applications and may be used as an alternate

37 siderable promise for diverse biomedical and biodefense applications.

38 a wide range of clinical, environmental, and biodefense applications.

39 of bacteria in food, water, and clinical and biodefense areas.

40 Ebola into the public health system and the biodefense armamentarium is of the highest priority if f

41 rax disease progression, spore detection for biodefense, as well as understanding cell clearance in g

42 and field-tested a now operational civilian biodefense capability that continuously monitors the air

43 reatening diseases in humans, is of national biodefense concern because of its potential use as a bio

44 naviruses remain a serious public health and biodefense concern.

45 these viruses pose serious public health and biodefense concerns.

46 sative agent of anthrax, poses a significant biodefense danger.

47 established list of Select Agents related to biodefense-diarrheagenic Escherichia coli, Shigella spp.

48 ions in fields such as clinical diagnostics, biodefense, forensics, and DNA sequencing.

49 islation was ratified, a survey reveals that biodefense funding has thus far produced only a handful

50 Largely driven by the U.S. biodefense funding programs and reinforced by the 2014 o

51 The Working Group on Civilian Biodefense has developed consensus-based recommendations

52 The Working Group on Civilian Biodefense has developed consensus-based recommendations

53 The Working Group on Civilian Biodefense has developed consensus-based recommendations

54 f the many recent developments using SERS in biodefense, human and animal health, and monitoring food

55 BoNT/A intoxication and could have potential biodefense implications.

56 oncerns of antibiotic-resistant bacteria and biodefense, it has become important to rapidly identify

57 rapid characterization of microorganisms in biodefense or medical diagnostics usually detect intact

58 nstitutes of Health as a category B priority biodefense pathogen in the United States.

59 l/disulfide redox biology of this category A biodefense pathogen.

60 acteria Francisella tularensis, a category A biodefense pathogen.

61 s for Disease Control and Prevention; from a biodefense perspective, source attribution is vital in a

62 To overcome this limitation in our biodefense preparedness, we have designed monoclonal ant

63 The NIAID-funded Biodefense Proteomics Resource Center (RC) provides stor

64 of their use for infectious diagnostics and biodefense-related diagnostics seems obvious.

65 eless, the application of DNA microarrays to biodefense-related diagnostics will depend on solving a

66 ommunity--what are the permissible limits of biodefense research and how can knowledge in the life sc

67 Biodefense research creates a conundrum for the scientif

68 As biodefense research expands to counter the threat of bio

69 The NIAID Resources for Biodefense Research program is forging new collaboration

70 aged the entire spectrum of conventional and biodefense resources.

71 A key to biodefense strategies is an assessment of current therap

72 ive Viral Bioinformatics Resource Center for Biodefense that will be one of the National Institute of

73 a higher potency glycoform offer promise as biodefense therapeutics.

74 impact on public health and pose a credible biodefense threat, but the development of safe and effec

75 regions of endemicity as well as a credible biodefense threat.

76 approved treatments for most of these viral biodefense threats.

77 cations ranging from clinical diagnostics to biodefense to food testing; advances in those applicatio

78 sis was established for future evaluation of biodefense vaccine candidates.

79 ial to improve the efficacy of rPA and other biodefense vaccines.